ClinicalTrials.gg
CompletedNCT03884452Updated May 10, 2024

Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)

A Phase 3 interventional study of Atorvastatin and Simvastatin in Familial Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 18 years 10 months after the study started (first participant enrolled May 2000, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy and the safety of ezetimibe (SCH 58235) co-administered with either atorvastatin or simvastatin in participants with homozygous familial hypercholesterolemia (FH).

02

Conditions studied

  • Familial Hypercholesterolemia
03

In context

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

This study's enrollment of 50 is below the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.

Browse Hyperlipoproteinemia Type II studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With a diagnosis of homozygous familial hypercholesterolemia
  • All females must have a negative pregnancy test prior to study entry. Women of child bearing potential must agree to practice an effective barrier method of for the duration of the study, until one month after treatment.
  • women who are receiving postmenopausal hormonal therapy or raloxifene must be maintained on a stable estrogen (ERT), estrogen/progestin (HRT) or raloxifene regimen during the study period. ERT, HRT or raloxifene cannot be changed during study period.
  • Must follow prescribed or stricter diet, and demonstrate completion of Diet Diaries

Exclusion criteria

Exclusion Criteria:

  • A history of mental instability, drug or alcohol abuse; or have been treated or are being treated for severe psychiatric illness which, in the opinion of the Investigator, may interfere with optimal participation in the study.
  • With underlying disease likely to limit life span to less than 1 year.
  • Have previously been randomized in any studies examining ezetimibe
  • Pregnant or lactating women.
  • With known or any to statin therapy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Atorvastatin 80 mg

    80 mg atorvastatin taken orally, once daily for 12 weeks

    Drug: Atorvastatin · Drug: Placebo for Ezetimibe

  • Experimental
    Ezetimibe + Atorvastatin 40 mg

    10 mg ezetimibe and 40 mg atorvastatin taken orally, once daily for 12 weeks

    Drug: Atorvastatin · Drug: Ezetimibe

  • Experimental
    Ezetimibe + Atorvastatin 80 mg

    10 mg ezetimibe and 80 mg atorvastatin taken orally, once daily for 12 weeks

    Drug: Atorvastatin · Drug: Ezetimibe

  • Experimental
    Simvastatin 80 mg

    80 mg simvastatin taken orally, once daily for 12 weeks

    Drug: Simvastatin · Drug: Placebo for Ezetimibe

  • Experimental
    Ezetimibe + Simvastatin 40 mg

    10 mg ezetimibe and 40 mg simvastatin taken orally, once daily for 12 weeks

    Drug: Simvastatin · Drug: Ezetimibe

  • Experimental
    Ezetimibe + Simvastatin 80 mg

    10 mg ezetimibe and 80 mg simvastatin taken orally, once daily for 12 weeks

    Drug: Simvastatin · Drug: Ezetimibe

Interventions

  • Tablets taken orally once daily in the morning

  • Tablets taken orally once daily in the morning or evening

  • Tablet taken orally once daily in the morning or evening

  • DrugPlacebo for Ezetimibe

    Tablets taken orally once daily in the morning or evening

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C) measured directly

    Time frame: Baseline and Up to Week 12

  2. Percentage of participants with an Adverse Event (AE)

    Time frame: Up to Week 12

Secondary outcomes

  1. Percent change from baseline in calculated LDL-C

    Time frame: Baseline and Up to Week 12

  2. Percent change from baseline in Total Cholesterol (TC)

    Time frame: Baseline and Up to Week 12

  3. Percent change from baseline in Triglycerides (TG)

    Time frame: Baseline and Up to Week 12

  4. Percent change from baseline in High-density-lipoprotein cholesterol (HDL-C)

    Time frame: Baseline and Up to Week 12

  5. Percent change from baseline in High-density-lipoprotein 2 cholesterol (HDL2-C)

    Time frame: Baseline and Up to Week 12

  6. Percent change from baseline in High-density-lipoprotein 3 cholesterol (HDL3-C)

    Time frame: Baseline and Up to Week 12

  7. Percent change from baseline in Apolipoprotein A-I (Apo A-I)

    Time frame: Baseline and Up to Week 12

  8. Percent change from baseline in Apolipoprotein B (Apo B)

    Time frame: Baseline and Up to Week 12

  9. Percent change from baseline in Lipoprotein(a) [Lp(a)]

    Time frame: Baseline and Up to Week 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gagne C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002 May 28;105(21):2469-75. doi: 10.1161/01.cir.0000018744.58460.62. PubMed 12034651 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2000 to primary completion in May 2001, 12 months.

Of 29 industry-sponsored phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 12 months is below that.

Counting every sponsor, half of 33 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2019
First posted
Mar 21, 2019
StartActual
May 3, 2000
Primary completionActual
May 24, 2001
CompletionActual
May 24, 2001
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03884452
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Mar 21, 2019
Start date
May 3, 2000
Primary completion
May 24, 2001
Completion
May 24, 2001
Last update
May 10, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Simvastatin · Ezetimibe

Start the discussion